Shareholders Approve Massive Share Increase, Reverse Split, and New CFO Appointment
LGVN sits 39% above its 52-week low of $0.475 on elevated volume (2.1× avg).
Summary
Longeveron shareholders approved a reverse stock split, a massive increase in authorized shares, and an expanded equity incentive plan, while the company also appointed a new CFO and director.
Key Events · Corporate Governance and Compliance · LGVN
-
Shareholders Approve Reverse Stock Split
Stockholders approved an amendment to the company's charter to effect a reverse stock split at a ratio of 1:2 to 1:20, with the exact ratio to be determined by the Board. This action is typically taken to boost the per-share price to meet exchange listing requirements.
-
Massive Increase in Authorized Shares
Shareholders approved an amendment to increase the number of authorized shares of Class A common stock to 175,000,000. This provides the company with significant capacity for future capital raises, but also represents substantial potential dilution for existing shareholders.
-
Expanded Equity Incentive Plan
The 2021 Incentive Award Plan was amended to increase the number of shares authorized by 5,000,000, which will be used for equity compensation and adds to potential dilution.
-
New Chief Financial Officer Appointed
Marie Washburn, previously the company's Vice President and Corporate Controller, was appointed as Senior Vice President and Chief Financial Officer, effective July 13, 2026. She succeeds Lisa Locklear, whose departure was previously announced.
Analysis · LGVN · Life Sciences
Shareholders have approved critical measures for Longeveron, including a reverse stock split (1:2 to 1:20) to address Nasdaq listing requirements and a substantial increase in authorized Class A common stock to 175,000,000 shares. These actions, alongside an expanded equity incentive plan, provide the company with significant flexibility for future capital raises and compensation, but signal a challenging financial position and carry a high potential for substantial dilution for existing shareholders. The appointment of an internal candidate as CFO provides continuity amidst these strategic shifts.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 43.6% of the 289 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LGVN was trading at $0.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.5M. The 52-week trading range was $0.48 to $1.80. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.